Background: Sclerostin (SC) is a monomeric glycoprotein expressed by osteocytes
Methods: This was a cross-sectional study involving 46 patients aged 55 to 80 years (mean, 71.1 ± 6.7 years, 36 men, 15 patients with T2D) who underwent carotid endarterectomy. Immunohistochemical levels of SC were evaluated in the atherosclerotic plaques by double-staining immunochemistry, and serum SC levels were evaluated by enzyme-linked immunosorbent assay.
Results: Sclerostin was present in the atherosclerotic plaques of all subjects investigated and increased significantly in the media compared with the intima (P < 0.0001) as well as in vascular smooth muscle cells (VSMCs) compared with the infiltrating macrophages (P < 0.0001). However, no significant difference in SC expression was observed between patients with and without T2D. No correlation was found between serum and immunohistochemical levels of SC; significantly increased SC serum levels were detected in males compared with females (P = 0.049).
Conclusions:
We have demonstrated, for the first time, the expression of SC in VSMCs of atherosclerotic plaques, suggesting a potential role for this protein in the development of atherosclerosis. Further studies are needed to understand if the role played by SC is detrimental or protective in the atherosclerotic disease process.
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| INTRODUCTION
The pathophysiological pathways leading to the development of atherosclerosis are no longer attributed only to high lipid content, as endothelial damage, reactive oxygen species, and the calcification process also play pivotal roles leading to the development of atherosclerosis. 1, 2 Several recent studies have highlighted the role played by bone molecules in vascular calcification and atherosclerosis. 3 A large 2 | MATERIALS AND METHODS
| Study design and population
In this cross-sectional study, we consecutively screened patients who age 71.2 ± 6.7 years) were enrolled in the study, and 15 patients had T2D (12 men, three women, mean age 72.8 ± 6.8 years, disease duration 7.3 ± 9.6 years). Sixteen subjects were not included in the study, as they did not match the inclusion criteria: Five subjects were excluded due to diagnosis of osteoporosis; three subjects for diagnosis of neoplasia in the previous 5 years; two subjects were excluded for previous femoral fracture; and four subjects for knee and hip replacement surgery. Finally, two subjects did not meet the entry criteria, as they had a previous diagnosis of autoimmune disease.
The anthropometric and clinical parameters of the patients are shown
in Table 1 .
This study protocol was approved by the local ethics committee and was conducted according to the Declaration of Helsinki. All participants gave written informed consent before being enrolled in the study, and the following information was collected in a structured interview: age, weight, height, smoking status, history of cardiovascular disease and presence of diabetes, and treatment. Blood pressure
was measured with a mercury sphygmomanometer after the patient had been seated for at least 5 minutes.
| Biochemical measurements
A venous blood sample was drawn from all participants 1 hour before surgery. All samples were centrifuged, and the serum was stored in aliquots at −80°C for subsequent assay. 
| Immunohistochemistry
The slides were incubated with 0.5% H 2 0 2 -methanol to block endog- 
| Morphological analysis
Two independent pathologists classified the atherosclerotic lesions using the Virmani classification 21, 22 and identified four phases: early atheroma, advanced atheroma, fibrocalcific lesions, and rupture.
Immunohistochemical expression of SC was evaluated using a semiquantitative method. Sclerostin staining was assessed in the carotid vessels (intima and media tunica) and in the different histological components (macrophages, lymphocytes, and VSMCs). Finally, SC staining was evaluated in the core of the plaques. The results were expressed using five levels of expression based on the intensity of expression and distribution of SC (−, absent; −/+, mild and focal; +, mild; ++, moderate; and +++, intense and diffuse).
| Enzyme-linked immunosorbent assay
Serum SC was measured in all patients with a quantitative sandwich enzyme-linked immunosorbent assay (ELISA) kit (DSST00 Quantikine, R&D Systems, Minneapolis, Minnesota) according to the manufacturer's instructions. The manufacturer-reported intra-assay precision for SC was 1.8% to 2.1%, and inter-assay precision was 8.2 to 10.8.
The measurements are reported in picograms per microliter, and the lower limit of detection was <1.74 pg/mL.
| Statistical analysis
All statistical analyses were performed using SAS version 9. 3 | RESULTS
| Immunohistochemical staining of SC
The presence of SC in the core of the plaques was detected in 100.0%
of the patients ( Figure 1C ).
Sclerostin expression in the tunica media increased significantly compared with that in the intima (95.6% vs 13.0% of patients, respectively) (P < 0.0001) (Figure 2 ).
Sclerostin was not detectable in lymphocytes, whereas it was significantly present in macrophages (SC presence: 100.0% of patients, P < 0.0001) and VSMCs (SC presence: 96.5% of patients, P < 0.0001) ( Figure 1D) .
We determined the possible differences in SC expression between VSMCs and macrophages considering the specific roles of the different cells in the vascular wall of the atherosclerotic plaques. Sclerostin localization (%) taking into account the tunica (media and intima), the core of the plaque, and the different cell types. The P values reflect comparisons between two specified subgroups (T2D vs no T2D).
The moderate level increased significantly in the VSMCs compared with that in macrophages (26.2% vs 0.0%, P < 0.0001), whereas the mild level increased significantly in the macrophages compared with that in the VSMCs (47.6% vs 0.0%, P < 0.0001).
No difference in SC expression was observed after subdividing the patients based on the presence of T2D ( and HDL cholesterol, and SC expression in the intima and media (age P = 0.9, gender P = 0.051, hypertension P = 0.86, diabetes P = 0.75, and LDL P = 0.58 and HDL cholesterol P = 0.87) and core (age P = 0.47, gender P = 0.49, hypertension P = 0.48, diabetes P = 0.28, and LDL P = 0.78 and HDL cholesterol P = 0.51), such as in the different cells types (age P = 0.67, gender P = 0.64, hypertension P = 0.71, diabetes P = 0.73, and LDL P = 0.94 and HDL cholesterol P = 0.61) ( Table 3 ).
| Circulating levels of SC
Serum SC levels increased significantly in males compared with those in females (SC 123.6 ± 48.1 and 92.7 ± 31.0 pg/mL, respectively, P = 0.049). No differences were found when patients were subdivided according to the presence of diabetes (SC in patients with diabetes 123.1 ± 39.6 pg/mL, P = 0.34, and without diabetes 113.5 ± 49.8 pg/ mL); hypertension (SC in patients with hypertension 116.4 ± 47.8 pg/ mL, P = 0.61, and without hypertension 119.0 ± 48.3 pg/mL); previous ischaemic heart disease (SC in patients with ischaemic heart disease 119.0 ± 53.8 pg/mL, P = 0.96, and patients without ischaemic heart disease 115.2 ± 41.8 pg/mL); or smoking habit (SC in smoker patients 117.0 ± 53.6 pg/mL and no smokers 113.5 ± 38.3 pg/mL, P = 0.99).
No correlations were observed between SC and age, weight, body mass index (BMI), FBG, HbA1c, total cholesterol, LD, HDL, triglycerides, uric acid, calcium, phosphorus, vitamin D, urea, creatinine, CDK-EPI, CK-MB, or the D-dimer.
We also found no significant correlations between serum levels of SC and immunohistochemical staining for SC (data not shown).
| DISCUSSION
In the present study, we demonstrated the presence of SC in atherosclerotic plaques isolated from carotid arteries by CEA in subjects affected by severe vascular disease. We did not observe any differences between patients with and without T2D.
Calcification of the arteries occurs via an active process that resembles bone formation. An essential step during the development of arteriosclerosis is the trans-differentiation/calcification of VSMCs resembling osteogenesis. 4, 7 Several in vitro studies have demonstrated that osteoblast-like cells and their products are involved in both bone and vascular calcification, suggesting the existence of a bone-vascular axis. 4 Sclerostin is one of the molecules involved in the bone-vascular axis, and its expression is not restricted only to the bone, but extraosseous SC expression has been observed in calcifying VSMCs and aortic valves.
11,23
In our study, SC increased significantly in the tunica media compared with that in the intima. Our findings seem to confirm the strict relationship between the bone and vascular system. In particular, when we analysed SC localisation in different cell types of the plaques, SC increased significantly in VSMCs compared with that in macrophages, which are involved in calcification and in inflammatory processes of the arterial wall, respectively.
Vascular smooth muscle cells modulate the response that normally follows mechanical vessel injury and inflammation. 23 Sclerostin is also expressed in aortic VSMCs, 24 and its serum levels are up-regulated during arteriosclerotic calcification, which limits vascular remodelling and predisposes the patient to aneurysm formation. 24 We found no association between serum levels and SC immunohistochemical staining, suggesting that it may be produced by VSMCs in plaques. production and systemic levels of SC play in the development of atherosclerosis.
Different hypotheses can be proposed. Sclerostin could play a protective role by inhibiting vascular calcification, as suggested by the increased serum levels of SC in chronic kidney disease (CKD) 13, 26 and SC added to Dickkopf-1 (DKK1) in patients with acute ischaemic stroke. 27 Extra-skeletal SC may be part of a normal feedback mechanism and may contribute substantially to its circulating levels and could be a counter regulatory mechanism to suppress the progression of vascular calcification. 14 who observed an association of circulating SC with coronary artery calcification, found that high serum levels of both SC and DKK1 were associated with acute ischaemic stroke. 27 They hypothesized that circulating concentrations of these proteins may partly reflect their production and secretion by cells of the vasculature. These results indicate that SC and DKK1, produced in vascular walls, may get into the circulation, leading to an increased serum levels of these proteins. 27 In contrast, SC could play a detrimental role by inhibiting vascular calcification, which is a physiological process used to limit the possible complications of atherosclerosis, such as vascular thrombosis, stenosis, or rupture. Moreover, this second hypothesis could explain the slight increase in cardiovascular events observed during treatment with romosozumab. 19 Contrasting results have been observed regarding the role of T2D in SC expression. 12, 30 In our study, T2D did not affect either serum levels or immunohistochemical staining of SC. In addition, the possible confounding factors of age, gender, hypertension, and LDL-and HDLcholesterol were not associated with SC expression in plaques, confirming the possible role of SC in the development of atherosclerosis.
Our study had several strengths and some limitations. This is the first time that SC has been evaluated in atherosclerotic plaques of patients without osteoporosis, bone disease, and CKD or in those undergoing haemodialysis.
However, our work presents some limitations. First, this is a pilot study that was carried on in a single-centre study. Second, a limited number of subjects have recruited in particular affected by T2D. Third, the main limitation of our study is the lack of mRNA evaluation, which would be extremely useful to confirm SC production by VSMCs.
Furthermore, although SC expression seemed not to be affected by different plaque stages, suggesting that it is diffusely expressed during atherosclerotic development, the relatively small number of fibrocalcific and ruptured lesions in our study may have been a limitation for the statistical analysis, so further studies are needed to confirm this finding.
In conclusion, we found SC expression in the tunica media of VSMCs in plaques from patients affected by severe atherosclerosis, suggesting a role played by this protein in the development of atherosclerosis. Further studies are needed to confirm our findings and determine if SC plays a detrimental or protective role during atherosclerotic disease.
